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Abstract
Comparative genomic hybridisation
(CGH) is a technique that permits the
detection of chromosomal copy number
changes without the need for cell cultur-
ing. It provides a global overview of chro-
mosomal gains and losses throughout the
whole genome of a tumour. Tumour DNA
is labelled with a green fluorochrome,
which is subsequently mixed (1:1) with red
labelled normal DNA and hybridised to
normal human metaphase preparations.
The green and red labelled DNA frag-
ments compete for hybridisation to their
locus of origin on the chromosomes. The
green to red fluorescence ratio measured
along the chromosomal axis represents
loss or gain of genetic material in the
tumour at that specific locus. In addition
to a fluorescence microscope, the tech-
nique requires a computer with dedicated
image analysis software to perform the
analysis. This review aims to provide a
detailed discussion of the CGH technique,
and to provide a protocol with an empha-
sis on crucial steps.
(J Clin Pathol:Mol Pathol 1999;52:243–251)
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Comparative genomic hybridisation (CGH) is
a technique that permits the detection of chro-
mosomal copy number changes without the
need for cell culturing. It gives a global
overview of chromosomal gains and losses
throughout the whole genome of a tumour.
Thus, CGH is a relatively fast screening
technique that can point at specific chromo-
somal regions that might play a role in the
pathogenesis or progression of tumours.
Guided by CGH results,more specific molecu-
lar biological techniques (such as fluorescence
in situ hybridisation, loss of heterozygosity
analysis, and sequencing) can be used to iden-
tify oncogenes and/or tumour suppressor genes
in these regions.
Kallioniemi et al at the University of Califor-
nia, San Francisco were the first to report
CGH as a new chromosome analysis technique
in 1992,1 shortly followed by du Manoir et al.2
In short, tumour DNA is labelled with a green
fluorochrome, mixed (1:1) with red labelled
normal DNA, and hybridised to normal
human metaphase preparations. The normal
reference DNA and the metaphases are
obtained from a healthy volunteer and do not
need to be from the patient. The green and red
labelled DNA fragments compete for hybridi-
sation to their locus of origin on the chromo-
somes. The green to red fluorescence ratio
measured along the chromosomal axis repre-
sents loss (ratio < 1) or gain (ratio > 1) of
genetic material in the tumour at that specific
locus (figs 1 and 2). In addition to fluorescence
Figure 1 Principle of comparative genomic hybridisation (CGH). Schematic overview of
the CGH technique. Tumour and reference DNA are labelled with a green and red
fluorochrome, respectively, and hybridised to normal metaphase spreads. Images of the
fluorescent signals are captured and the green to red signal ratios are quantified digitally for
each chromosomal locus along the chromosomal axis.
Tumour DNA
Green: FITC
Hybridisation
Digital image
processing
Red Green
Fluorescence ratio
0.75 1.25
Gain
Loss
1.0
Fluorescence
microscopy
Normal DNA
Red: TRITC
Cot-1 DNA
Normal human metaphase
Figure 2 High level gain on the long arm of chromosome
12. The clear green band shows the high level gain or
amplification on the long arm of chromosome 12 in a
carcinosarcoma of the nasopharynx (chromosomal band
12q15). In addition, the comparative genomic hybridisation
(CGH) profile displays a green to red ratio >> 1. Because
of suboptimal blocking of repetitive DNA sequences in the
profile, another peak appeared at the site of the centromere,
which was interpreted as an artefact and neglected when
interpreting CGH results.3
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microscopy, the technique requires dedicated
computer software for the analysis of results.
Initially, it appeared to be rather diYcult to
perform the technique in other, less specialised
laboratories, and it was only after the publi-
cation of an article reviewing the method in
more detail, and after the necessary software
became commercially available, that CGH
became more accessible.4 Because no cell
culturing is required for CGH, this technique
has enabled tremendous progress in the analy-
sis of chromosomal changes in solid tumours.
Applications of CGH in cancer research
include screening of tumours for genetic
aberrations,5–18 searching for genes involved in
the carcinogenesis of particular subsets of
cancers,19 analysing tumours in experimental
models to obtain an insight into tumour
progression,20 diagnostic classification,19 and
prognosis assessment.21 At present, CGH is
performed in a growing number of laboratories
and a wide variety of tumours have been
analysed (fig 3). Apart from these oncological
applications, CGH analysis has also been used
to study chromosomal aberrations in fetal and
neonatal genomes.22–24
Until now, over 300 articles on CGH have
been published by research groups from several
countries, including reviews25–27 and technical
papers28–45 (fig 4). This boom is caused mainly
by the reduced demands on the material used
for CGH. It has become possible to use archi-
val formalin fixed and paraYn wax embedded
material, whereas initially only DNA from
fresh and frozen tumours and material from
cell lines could be used. In addition, by using
techniques such as microdissection and degen-
erate oligonucleotide primed polymerase chain
reaction (DOP-PCR), CGH became applica-
ble to smaller lesions. However, the high
number of technical reports indicates that
CGH is still viewed as a relatively diYcult
method. Therefore, we aim to provide a
detailed discussion of the CGH technique, and
to provide a protocol with an emphasis on cru-
cial steps.
Sensitivity and limitations
CGH is a relatively time consuming and
diYcult technique with a number of limita-
tions. It cannot detect structural chromosomal
aberrations without copy number changes,
such as balanced chromosomal translocations,
inversions, or ring chromosomes, and it does
not yield information in the context of tissue
architecture. CGH detects gains and losses
relative to the ploidy level. It also has the
disadvantage of being less sensitive than PCR
based methods in detecting deletions. CGH
results are not linearly distributed. Theoreti-
cally, the loss or gain of one copy of a certain
chromosome in a diploid genome should result
in a fluorescence ratio of 0.5 or 1.5. However,
in experiments comparing male and female
DNA, where the fluorescence ratio for the X
chromosome should be 0.5 or 2.0, these ratios
are never found in practice.
The sensitivity of CGH can be hampered by
contamination of tumour material with normal
cells, which will be explained in detail else-
where in this article. Furthermore, the sensitiv-
ity of CGH depends on the level and size of the
copy number changes. Based on simulation
experiments, a copy number increase of 50%
should be detectable if the region is 2 megabase
pairs (Mb) or larger, and an amplified region
(amplicon) of 250 kilobase pairs (kb) would
need a 400% copy number increase.46 The
lower limit of detection is determined by the
product of the excess copy number and the size
of the amplified region. When the deletion is
100% (no copies present), a resolution of
1–2 Mb can be achieved.43 Based on CGH
experiments, the crucial detection size was
estimated to be in the range of 10–20 Mb.3 32 47
Description of the protocol and problem
areas of CGH
METAPHASE SLIDE PREPARATION
Metaphase chromosomes are prepared accord-
ing to standard protocols using phytohaemag-
glutinin stimulated peripheral blood lym-
phocytes from a karyotypically normal man or
woman. Because women have two X chromo-
somes and the Y chromosome does not contain
much genetic information, it is preferable to
use metaphase spreads from women. High
quality metaphase preparations for CGH
should ideally have little cytoplasm (too much
cytoplasm causes high background levels and
may prevent optimal denaturation), minimal
overlapping of the chromosomes (overlapping
chromosomes need to be excluded from CGH
analysis), and low cell density paired with a
Figure 3 Diversity of tumours analysed by comparative
genomic hybridisation (CGH) and types of reports
(1992–8). Categories are: (1) neurological tumours; (2)
tumours of the male genital tract; (3) tumours of the
urinary tract; (4) breast cancer; (5) haematological
diseases; (6) tumours of the digestive tract; (7) lung cancer;
(8) tumours of the female genital tract; (9) soft tissue
tumours; (10) lymphomas; (11) oral tumours; (12) bone
cancer; (13) neuroendocrinal tumours; (14) skin cancer;
(15) technical reports; (16) reviews; (17) other types of
report.
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Figure 4 Number of comparative genomic hybridisation
(CGH) publications from 1992 to 1998.
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high mitotic index. In addition, the chromo-
somes should be of adequate length (400–550
bands) and not contain separated chromatids.
Finally, for good banding strength, chromo-
somes should appear dark, not shiny, when
looking through a phase contrast microscope.36
In short, 1 ml of heparinised blood is added
to 10 ml Ham F10 culture medium (Gibco
BRL, Breda, Netherlands) containing fetal calf
serum (10%), L-glutamine (1%), penicilin and
streptomycin (1%), and phytohemagglutinin
(1.5% in distilled water) and incubated at 37°C
in an atmosphere of 5% CO2 for 72 hours.
Cells are arrested in mitosis by the addition of
colchicine to a final concentration of 0.01 µg/ml,
harvested, treated with hypotonic KCl
(0.075 M) and fixed in 3:1 methanol/acetic
acid. A crucial step in the procedure is the
dropping of the fixed cell solution on to the
slides. The success of this step is dependent on
many factors (such as weather conditions, cell
suspension quality, and laboratory conditions),
but in our hands it is best to drop the cell sus-
pension from a distance of ∼ 30 cm on to etha-
nol cleaned slides. Usually, one drop of the cell
suspension results in a suYcient number of
metaphase spreads for one CGH experiment.
Optimal conditions are a room temperature of
24°C and a relative humidity of 60–70%. The
slides should be evaluated with a phase
contrast microscope. If large amounts of
residual cytoplasm are still visible on the slides,
the fixation step (3:1 methanol/acetic acid)
should be repeated a few times. In addition, a
postfixation step—dropping 3:1 methanol/
acetic acid on to a vertically positioned slide—
might be helpful in removing cytoplasm. Slides
are air dried (“aged”) overnight at room
temperature and stored at −20°C in groups of
four, in the presence of either silica beads or
nitrogen to keep them dry. It is important to
test several batches of metaphase slides from
diVerent donors when setting up CGH experi-
ments, because their behaviour in hybridisation
can be variable (fig 5). Alternatively, fully pre-
pared metaphase slides are commercially avail-
able (Vysis, Downers Grove, Illinois, USA;
catalogue number: 30-806010). However,
these slides still need to be tested before use,
and the quality is not necessarily better than
that of slides produced in house, as described
above.
DNA ISOLATION FROM TUMOUR TISSUE
The quality of DNA is a very important issue
when performing CGH. DNA extracted from
fresh or frozen tissue is usually of high molecu-
lar size (not degraded) and will be of the best
quality for labelling purposes. However, when
using formalin fixed, paraYn wax embedded
tissue, the extracted DNA will be partly
degraded (300–20 000 bp) and crosslinked.
The quality of DNA from paraYn wax embed-
ded tissues depends greatly on the pH of the
formalin fixative, and on the duration of
fixation; thus, neutral buVered formalin
(pH 7.0) and fixation for no longer that 24
hours usually preserves DNA of suYcient
quality. During the labelling process, by means
of nick translation (that is, cutting DNA and
substituting unlabelled nucleotides with dig-
oxigenin, biotin, or fluorochrome labelled
nucleotides), DNA becomes even shorter and,
in the case of formalin fixed material, the DNA
fragments may become too small for optimal
CGH experiments. The crosslinking of DNA
caused by the fixative can hamper the function
of the enzymes, DNA polymerase and DNase,
resulting in impaired incorporation of modified
nucleotides. This will lead to an irregular and
speckled hybridisation pattern of the met-
aphase chromosomes. As a result, diVerences
in staining intensities between reference and
tumour DNA are less pronounced.
Both the standard phenol extraction
method19 21 28 and commercially available DNA
isolation kits, based on aYnity columns, can be
used and optimised for paraYn wax embed-
ded, formalin fixed tissue. For paraYn wax
embedded material in general, a series of
10–20 sections of 10 µm is suYcient to obtain
4–20 µg of DNA, depending on the amount
and cellularity of the tissue. To reduce the
number of crosslinks between the DNA strands
in formalin fixed material, an overnight incuba-
tion at 37°C with 1 M sodium thiocyanate
might be helpful. A prolonged incubation
period (three days) with lysis buVer (155 mM
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA,
pH 7.4) and high concentrations of proteinase
K (final concentration 2 µg/µl, freshly added
twice a day) yields a suYcient quantity of rela-
tively good quality DNA from paraYn wax
embedded material. A protocol for the extrac-
tion of DNA from formalin fixed, paraYn wax
embedded tissue, using aYnity columns, is
given in appendix 1.
CONTAMINATION
Contamination (or dilution) of the tumour
DNA with normal DNA (for example, from
stromal and inflammatory cells) is an undesir-
able but inevitable problem when analysing
tumours. The eVect on CGH results will be
that the green to red ratio shifts towards 1.0, so
Figure 5 EVect on comparative genomic hybridisation (CGH) results of diVerences in
blocking eYciency between metaphases of diVerent individuals.Metaphase slides of
lymphocyte suspensions of two healthy individuals were prepared using standard procedures.
On these metaphases, CGH experiments of the same tumour versus normal DNA was
performed with the same amount of Cot-1 DNA.Blocking eYciency diVered between
chromosomes from diVerent individuals (A v B) and insuYcient blocking (individual A)
caused repression of the amplitude of the green to red ratio.
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that if the tumour sample contains too much
normal DNA, chromosomal aberrations can go
undetected. In a triploid tumour, a single copy
gain (4:3) or loss (2:3) becomes undetectable
at 50% contamination, whereas in a diploid
tumour a single copy gain (3:2) or loss (1:2)
disappears at 75% contamination (fig 6).
Therefore, whenmore than 75% of the cells are
neoplastic, whole sections can be processed. In
cases when the tumour content is less than
75%, tumour tissue can be microdissected
from the sections by demarcating with a
marker, scraping it oV with a surgical blade,
and collecting it in Eppendorf tubes (fig 7A
and B). In addition, advanced laser microdis-
section equipment can be used49; however, this
is expensive and often not necessary. Inflam-
matory cells are particularly hard to dissect
because they have usually infiltrated the
tumour. Cell sorting techniques (for example,
antibodies attached to magnetic beads or flow
cytometric sorting) might permit the selection
(and extraction) of tumour cells, or the
elimination of inflammatory cells, to produce a
more purified tumour DNA sample.
AMOUNT OF DNA
Approximately 0.5–1 µg of DNA is required for
one CGH experiment. In the case of carcino-
mas this is usually not a problem. However,
small samples—for example, biopsies from
premalignant lesions, might not yield enough
DNA. In this situation, DOP-PCR35 50 and
other techniques51 have been used for DNA
amplification. Because of the non-random way
in which DOP-PCRmay amplify DNA it could
give unreliable results. Therefore, additional
control experiments (such as a repeated CGH
experiment with reverse labelled probes) need
to be included in every CGH experiment. In
our hands, CGH with DOP-PCR amplified
normal DNA hybridised against non-amplified
normal DNA yielded CGH profiles with
fluorescence ratios smaller or greater than 1.0.
When amplifying both test and reference DNA
with DOP-PCR, CGH profiles appeared to be
more reliable, but not as good as non-amplified
normal versus normal DNA (MM Weiss et al,
1998, unpublished results). In conclusion, if
enough DNA is available for performing CGH
without amplifying the DNA it is preferable not
to use DOP-PCR. However, if a lack of
suYcient DNA requires amplification, both
tumour and reference DNA should be ampli-
fied in the same way and control experiments
need to be performed simultaneously.
DNA LABELLING
A standard method (nick translation) is used to
label the DNA and digest the DNA to the opti-
mal fragment length of 500–1500 bp. A small
amount (0.5–1.0 µg) of DNA is suYcient.
Figure 6 EVect of contamination of tumour DNA with normal DNA on comparative genomic hybridisation (CGH)
results. DNA extracted from two tumour cell lines (92-VU040T and 93-VU120T,48 referred to hereafter as SCC-040 and
SCC-120, respectively, was contaminated (mixed) with normal DNA in diVerent concentrations and analysed by CGH.
Cell line 1 (SCC-040) is a diploid oral squamous cell carcinoma and cell line 2 (SCC-120) is a triploid oral squamous cell
carcinoma. Both cell lines were cytogenetically karyotyped, so most of the genetic aberrations were known. (A) The CGH
profiles of certain chromosomes from the diploid tumour; (B) the CGH profiles of certain chromosomes from the triploid
tumour. In the triploid tumour, a single copy gain (4:3) or loss (2:3) becomes undetectable at 50% contamination, whereas
in the diploid tumour, a single copy gain (3:2) or loss (1:2) disappears at 75% contamination. The 95% confidence
interval was used as the threshold.
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Figure 7 Microdissection of a 10 µm tissue section.
Example of a 10 µm haematoxylin stained tissue section in
which most of the tumour cell rich part was demarcated
(A) and scraped oV with a surgical blade (B). The scraped
oV tissue from 10–20 such sections is collected in an
Eppendorf tube for DNA extraction.
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When biotinylated and digoxigenin conjugated
deoxynucleotides (dUTPs) are incorporated
into the DNA (indirect labelling) after hybridi-
sation, a detection step with fluorochrome
conjugated antibodies (avidin–fluorescein iso-
thiocyanate (FITC) and sheep antidigoxigenin
–tetramethyl rhodamine isothiocyanate
(TRITC), respectively) is required. Deoxynu-
cleotides that have been directly conjugated
with fluorochromes render a smoother but
weaker hybridisation signal along the chromo-
somes. It is important that the labelled DNA
fragments of both tumour and reference DNA
are in the same range of lengths and are within
the limits of 500–1500 bp. This has to be
checked by electrophoresis on an ethidium
bromide stained 1% agarose gel. A protocol for
nick translation is given in appendix 2.
BLOCKING
Chromosomal regions with short repetitive
DNA sequences occur throughout the whole
genome, but in a high number at all centro-
meres, telomeres, and some specific regions
(chromosome arms 1p and 16p, and chromo-
somes 19 and 22). The lengths of these regions
are highly variable between individuals (and
thus between tumour and reference DNA),
and this can interfere with CGH analysis.
Therefore, repetitive DNA regions are blocked
with unlabelled Cot-1 DNA (placental DNA
from 50 to 100 bp, which is enriched for
repetitive DNA sequences). Suboptimal block-
ing, seen as non-black centromeres, can lead to
a reduced amplitude of the green to red ratio
(fig 5) and gains and losses may go undetected.
As an alternative to blocking, removal of
repetitive sequences from the probe may be
another solution to this problem.52
HYBRIDISATION
Aliquots of 300–350 ng of both tumour and
reference labelled DNA (the probes) are mixed
with 100 times the same amount of human
Cot-1 DNA, precipitated, and resolved in a 6 µl
hybridisation mix containing 50% formamide
(which decreases the melting temperature of
DNA) and 10% dextran sulphate (which
increases the eVective probe concentration), in
2× saline sodium citrate (SSC), pH 7.0. Sex
matching of the normal and the reference
labelled DNA is not necessary. In fact, the
resulting uneven fluorescence ratio for the X
chromosome could function as an extra control
of the quality of the experiment (blocking,
strength of the signal). However, sex matching
should be taken into account when analysing
the X chromosome. The probe and the normal
metaphase slides are denatured separately: the
slides in 70% formamide/2× SSC at 72°C for
5–10 minutes (depending on the metaphase
slide batch), and the probes in a water bath at
80°C for 10 minutes. The hybridisation takes
place under a coverslip in a humid incubator at
40°C for two to four days. After hybridisation,
the slides are washed and counterstained with
DAPI (0.35 µg/ml in an antifade solution
(Vectashield; Vector Laboratories, Burlingame,
California, USA) to produce a banding pat-
tern, which enables chromosome identification
and karyotyping. A protocol for hybridisation is
given in appendix 3.
Hardware and software requirements for
CGH
A detailed description of the hardware and
software requirements can be found
elsewhere.41 43 In brief, the analysis of CGH
preparations comprises the following steps.
VISUALISATION OF FLUORESCENCE
Visualisation of fluorescence of a metaphase for
DAPI (blue; for chromosome identification),
TRITC (red; normal reference DNA), and
FITC (green; tumour DNA) using a fluores-
cence microscope. The microscope, lamp,
objective, and the filters require special atten-
tion. Mercury arc lamp light sources are
adequate if they are stable and can be aligned
to give uniform illumination without chromatic
variation.Microscope alignment is crucial, and
should be given major attention. The objective
should be of the “plan” type, apochromatic,
and provide ×63 or ×100 magnification,
depending on the resolution of the camera (see
below). It should transmit UV light, and there
should be no lens autofluorescence. The filters
used should minimise the crosstalk between
the three fluorochromes, which means that
narrow band pass filters are required for
excitation and emission. However, as the band
width of a filter becomes narrower, the bright-
ness of the remaining signals diminishes, which
can result in long exposure times. Therefore,
filters should provide the best compromise
between crosstalk and brightness. Good filter
sets for the often used DAPI/TRITC/FITC
fluorochrome combination are commercially
available. The lateral shift caused during
changing between the filters should be
Figure 8 Comparative genomic hybridisation (CGH) analysis profile (stomach
carcinoma). Relative copy number karyotype showing the quantitative analysis of a CGH
experiment. The mean green to red fluorescence ratios of the chromosomes of multiple
metaphases are plotted on a graph corresponding to the chromosome ideograms.With CGH
analysis, the highly polymorphic centromeric and heterochromatic regions are excluded for
technical reasons.1 The relative copy number karyotype in this figure shows clear gains. The
most pronounced aberrations are: gains of whole chromosomes 2 and 7, the long arm of
chromosome 8, chromosome 13 (high level gain), chromosome 15, the long arm of 19, and
chromosome 20. Losses are seen at the tips of the long arms of chromosome 4, 5, and 12.
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minimal. An automatic filter wheel could
prevent this shift, but software correction is
also possible.
RECORDING THE IMAGE
The camera should provide a spatial resolution
of 0.1 µm at the specimen level, to give an
image of ∼ 600 × 600 pixels for the average
metaphase. It should be capable of integrating
the signal for the usual time of five to 10
seconds without generating dark current. An
8 bit photometric resolution is suYcient. The
camera should have a good linearity. In
practice, most commercially available modern
PAL-CCD video cameras will meet these
criteria. An expensive camera (such as high
resolution or cooled CCD) is therefore not
necessary for CGH. The computer type is
largely determined by the CGH software and
can be any UNIX, Macintosh, or Windows 95
based machine with adequate speed. The
image capture and storage time for each slide
(10–20 metaphases) is approximately one
hour. A high quality colour screen of suYcient
size (at least 17 inches) is required for adequate
display of the colour images and the graphical
user interface of the system.When selecting the
metaphases to capture, one should keep in
mind the following criteria: hybridisation
signals should be strong and homogeneous, not
granular; background should be minimal (no
residual cytoplasm); there should be minimal
overlapping of chromosomes; the chromo-
somes of all the metaphases should be in the
same length range (not extraordinarily long or
short). Capturing can be done both automati-
cally or manually in most software programs.
IMAGE PROCESSING
Dedicated CGH software (Applied Imaging,
Newcastle upon Tyne, UK;MetaSystems ISIS,
Belmont, Massachusetts, USA; Vysis Inc,
Downers Grove, Illinois, USA; PSI Power-
Gene, League City, Texas, USA; Leica, Cam-
bridge, UK; QCGH Leica, Cambridge, UK)
should enable the following steps to be carried
out: (1) background subtraction; (2) segmenta-
tion and removal of non-chromosome objects;
(3) normalisation of the FITC:TRITC ratio
for the whole metaphase; (4) interactive karyo-
typing; and (5) scaling of chromosomes to a
standard length, either for the whole chromo-
some or for each arm of the chromosome inde-
pendently. For the last option it is necessary to
position the centromeres correctly, which is
also an interactive feature.
The averaged ratios of several well selected
metaphases are plotted along ideograms
(showing schematically the G banding pat-
terns) of the corresponding chromosomes in a
so called relative copy number karyotype, pre-
senting chromosome areas that are lost (dele-
tions) or gained (amplifications). The
interpretation of the ratio profiles can be done
using either fixed or statistical thresholds.
Fixed limits of 0.75 and 1.25 or 0.85 and 1.15
can be used to identify losses and gains, while
others use the 95% confidence interval (CI)
limits of the ratio profile. In the latter,
deviations from normal are interpreted as gains
or losses when the 95% CI of the fluorescence
ratio does not contain 1.0. Chromosomal
regions 1p32–pter, 16p, and 19p should be
interpreted with extreme care, and to confirm
the CGH findings in these regions, it is recom-
mended that the experiment is repeated with
reversed probe labelling. This unreliability is
caused by the high amount of repetitive
sequences in these regions, which are variable
between individuals. The Cot-1 DNA should
repress these sequences (see blocking section)
but often this approach is only partially
successful. Figures 8 and 9 show the result of
CGH analysis of tumour (gastric carcinoma)
tissue versus normal tissue and of normal tissue
versus normal tissue, respectively. In the
control experiment, all ratio profiles are around
the 1.0 value, whereas in the tumour, devia-
tions can be seen at chromosome arms 2p, 2q,
7p, 7q, 8q, 13q, 19q, 20p, and 20q (gains) and
4q, 5q, and 12q (losses), using a 95% CI.
Figure 9 Comparative genomic hybridisation (CGH) control experiment. Relative copy
number karyotype of a CGH control experiment (green labelled normal DNA hybridised
versus red labelled normal DNA). All the calculated green to red ratios are located close to
the 1.0 line.
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Figure 10 Principle of microarray comparative genomic hybridisation (CGH). Schematic
overview of the CGH microarray technique. Tumour and reference DNA are labelled as for
“regular” CGH and hybridised to fragments of DNA (instead of metaphase chromosomes)
attached to a glass slide, ordered in arrays. Images of the fluorescent signals are captured
and the green to red signal ratios are measured digitally for each target.
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New developments
A new technique that is currently being devel-
oped in diVerent laboratories is the microarray
method. Using metaphase chromosomes for
hybridisation limits the detection of events
involving small regions (< 10–20 Mb) of the
genome. The array technique allows the detec-
tion of DNA copy number changes (genomic
DNA) in more detail, as well as analysing gene
expression using cDNA. Most publications so
far concern cDNA arrays.53–56 Pinkel et al
recently published an article on genomic DNA
microarrays,57 describing a method for the
measurement of copy number fluorescence
ratios on a set of clones that are located on
chromosome 20, with an average interval of
∼ 3 Mb. The technique provides a high resolu-
tion (± 40 kb) for measurement of gains and
losses of DNA sequences in genomes of mam-
malian complexity (fig 10). Shalon et al hybrid-
ised chromosomal probes to arrays of Saccharo-
myces cerevisiae genomic DNA fragments.58
Microarray CGH will enable the analysis of
genetic aberrations in cancer with a high reso-
lution, and will refine the allocation of crucial
genes. Moreover, in clinical applications it
could enable the identification of the status of
certain disease related genes. A detailed
discussion can be found elsewhere.59
Conclusions
CGH technology provides genome scale over-
views of DNA sequence copy number changes
in tumours, using almost any kind of clinical
specimen. It maps the origins of amplified and
deleted DNA sequences on normal chromo-
somes, thereby highlighting the locations of
important genes. However, to detect transloca-
tions, inversions, and small aberrations, addi-
tional techniques must be used. Therefore,
CGH supplements rather than replaces current
methods.
Appendix 1
DNA isolation protocol for formalin fixed, paraYn wax embedded tissue (10 µm sections,
haematoxylin stained) based on aYnity columns (QIAamp tissue kit; Qiagen, Valencia, California,
USA)
(1) If the tissue contains water, spin down for five minutes at maximum speed and decant the supernatant.
The next four steps are for unmicrodissected paraffin wax sections only (to remove the wax)
(2) Add 1 ml xylene, incubate for 10 minutes at 55°C, spin down, and decant supernatant (×3).
(3) Add 1 ml methanol, incubate for five minutes at room temperature, spin down, and decant supernatant
(×2).
(4) Spin down for five minutes and decant the supernatant.
(5) Add 1 ml 100% ethanol, vortex, spin down for five minutes, decant the supernatant (×2), and air dry the
pellet.
(6) Add 1 ml 1 M NaSCN and incubate at 37°C overnight.
(7) Spin down for five minutes and decant the supernatant.
(8) Add 1 ml phosphate buVered saline (PBS), vortex, spin down, and decant the supernatant (×2).
(9) Spin down for five minutes, decant the supernatant, and air dry the pellet.
(10) Add 200 µl ATL buVer and 40 µl proteinase K (10 mg/ml), vortex, and incubate overnight at 55°C.
(11) Add 40 µl proteinase K (10 mg/ml) and incubate at 55°C all day, vortex approximately every hour during
the day.
(12) Add 40 µl proteinase K (10 mg/ml) at the end of the day, incubate overnight at 55°C.
(13) Add 40 µl RNase A (20 mg/ml), vortex, and incubate for two minutes at room temperature.
(14) Add 400 µl AL buVer, vortex, and incubate for 10 minutes at 70°C.
(15) Add 420 µl 100% ethanol and vortex well.
(16) Place a QIAamp column in a QIAamp tube, apply the total volume of the sample (in steps of maximum
500 µl) on to the column, spin for one minute at 3000 ×g, decant the filtrate.
(17) Add 500 µl AW buVer and spin down for one minute at 8000 rpm, decant the filtrate.
(18) Add 500 µl AW buVer, spin down for three minutes at maximum speed and decant the filtrate.
(19) Place column into a new Eppendorf tube (not provided).
(20) Elute DNA with 75 µl AE buVer at 70°C, incubate for one minute at room temperature, and spin down
for one minute at 3000 ×g.
(21) Measure the DNA concentration the next day.
Appendix 2
Nick translation for comparative genomic hybridisation (CGH)
For a 30 µl reaction:
(1) Combine 1 µg of probe DNA, 3 µl of dNTP reaction mixture (0.2 mM dATP, dCTP, dGTP; 500 mMTris/
HCl, pH 7.8; 50 mM MgCl2; 100 µM dithiothreitol; 100 µg/ml bovine serum albumin), 0.5 µl of dTTP
(0.2 mM), 1 µl of digoxigenin or biotin conjugated dUTP (1 ng/µl), 3 µl of DNA polymerase I/DNase I
(Gibco BRL, Breda, The Netherlands), 0–1 µl diluted DNase I (Gibco BRL). Adjust volume to 30 µl with
double distilled water. Note, the amount of DNase I added varies for each DNA sample and is dependent
upon the DNase I batch (dilute freshly before use).
(2) Incubate for 1.5–2 hours at 15°C.
(3) Inactivate enzymes at 70°C for 15 minutes.
(4) Check fragment length by gel electrophoresis on an ethidium bromide stained 1% agarose gel (5 µl/sample).
Run at 100 V for 30 minutes. Inspect DNA fragment lengths with a UV transilluminator.
(5) For optimum hybridisation conditions, the probe (which is visible as a smear) should be between 500 and
1500 kb in length. If the probe size is larger, add more DNase I and 3 µl DNA polymerase I, incubate at
15°C for 15–30 minutes, and repeat steps 3 and 4.
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Appendix 3
Hybridisation
(1) Mix 8–12 µl of the labelled tumour (biotin) and labelled reference (digoxigenin) DNA.
(2) Add 40 µg Cot-1 DNA to the mixture of labelled DNAs.
(3) Ethanol precipitate sample: add 0.1× volume of 3 M NaAc and 2× volume EtOH, spin at 10 000 ×g for 30
minutes.
(4) Decant supernatant and air dry pellet.
(5) Dissolve pellet in 6 µl hybridisation mixture (50% deionised formamide, 10% dextran sulphate in 2× SSC,
pH 7.0. Store at −20°C).
(6) Denature metaphase slides in a jar with 70% formamide/2× SSC (20× SSC: 0.3 M sodium citrate, 3 M
NaCl, pH 7.0) in a waterbath at 80°C for five minutes (dependent on batch metaphase slides, the
temperature in the jar is ∼ 72°C).
(7) Dry slides in an ethanol series (70%/96%/100%).
(8) Denature DNA mixture in water bath (80°C) for 10 minutes and transfer to metaphase slide immediately.
(9) Cover with a sealed coverslip (18 × 18 mm).
(10) Hybridise for two to four days in a humid chamber at 40°C.
(11) Remove coverslips carefully.
(12) Wash for 5 minutes in 2× SSC at room temperature.
(13) Wash three times for five minutes each in 0.1× SSC at 45°C.
(14) Wash for five minutes in TNT (TNT: 50 ml 10× TN, 450 ml milli-Q, 1.25 ml 20% Tween-20; 10× TN:
1 M Tris/HCl, 1.5 M NaCl, pH 7.5 at room temperature).
(15) Preincubate for 10 minutes in 100 µl TNB (TNB: 0.5% blocking reagent (Roche Diagnostics, Almere, The
Netherlands) dissolved in 1× TN; before use, spin down undissolved particles and take the clear superna-
tant) under a coverslip (24 × 50 mm).
(16) Incubate for 60 minutes in 100 µl TNB with avidin–fluorescein isothiocyanate (FITC) (1:200) and sheep
antidigoxigenin–tetramethyl rhodamine isothiocyanate (TRITC) (1:50) under a coverslip (24 × 50 mm) in
a humid chamber at 37°C.
(17) Wash three times for five minutes each in TNT at room temperature.
(18) Wash for five minutes in 2× SSC at room temperature.
(19) Dry slide in an ethanol series (70%/96%/100%).
(20) Cover with 20–25 µl antifade containing DAPI (0.35 µg/µl) and seal with a coverslip (24 × 50 mm).
(21) Analyse slides with a fluorescence microscope and a digital image analysis system.
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